Trial reportAIDS (London, England)2026
Semaglutide improves markers of cardiovascular risk in people with HIV.
Trial report in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveSemaglutide improves cardiovascular disease (CVD) risk in people who are diabetic, overweight, or obese through incompletely understood mechanisms. To address this, we explored novel lipidomic and lipoprotein/glycoprotein profiling with semaglutide therapy.
designSecondary analysis of SLIM LIVER (ACTG A5371), an open-label, phase 2b, single-arm trial of 1 mg semaglutide weekly in adult people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease.
methodsParticipants ( n = 36) experiencing clinical response (>5 lb weight loss) to semaglutide were included. Lipidomic and lipoprotein/glycoprotein profiling was performed from stored serum.
resultsMedian age was 52 years and BMI 34 kg/m 2 ; 39% were Hispanic, 28% Black, 45% female, and 22% had stable statin use. Lipidomics: semaglutide reduced triglycerides, diglycerides, and sphingomyelins and increased some bile acids and phosphatidylcholines. Lipoproteins: CVD-linked species decreased; LDL particle size increased and large HDL particle number decreased. Glycoproteins: most participants had elevated baseline GlycA and GlycB, CVD-associated markers of systemic inflammation. 56% with elevated Glyc A improved and 32% normalized; 41% with elevated Glyc B improved and 42% normalized. Lipoprotein/glycoprotein concentrations generally did not correlate with baseline weight, liver fat, or insulin resistance or their magnitude of change.
conclusionIn this first human report of lipidomic and lipoprotein/glycoprotein profiling during semaglutide therapy in any population, lipidomic changes suggest reductions in toxic lipid species and improved hepatic insulin sensitivity. Significant reductions in CVD-risk associated lipoprotein/glycoprotein species were observed that did not correlate with magnitude of changes in weight, liver fat. or insulin resistance, suggesting an independent mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.